Evidence map›Paper›PMID 35242017›Full record

ReviewFrontiers in behavioral neuroscience2021

Emerging Role of Translational Digital Biomarkers Within Home Cage Monitoring Technologies in Preclinical Drug Discovery and Development.

Szczepan W Baran, Natalie Bratcher, John Dennis, Stefano Gaburro, Eleanor M Karlsson, Sean Maguire, Paul Makidon, Lucas P J J Noldus, Yohann Potier, Giorgio Rosati and 4 more

Abstract readReview
In one paragraph

Review in Frontiers in behavioral neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Validation framework forFrontiers in toxicology · 2024
    Review
  11. Biomarkers of stress resilience: A review.Neuroscience applied · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Benchmarking Enrichment Efforts in the US & Canada Across Species and Enrichment Categories.Journal of the American Association for Laboratory Animal Science : JAALAS · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Szczepan W BaranNovartis Institutes for BioMedical Research, Cambridge, MA, United States.
Natalie BratcherOffice of Global Animal Welfare, AbbVie, North Chicago, IL, United States.
John DennisUnited States Food and Drug Administration, Silver Spring, MD, United States.
Stefano GaburroTecniplast S.p.A., Buguggiate, Italy.
Eleanor M KarlssonCalico Life Sciences LLC, South San Francisco, CA, United States.
Sean MaguireGlaxoSmithKline, Collegeville, PA, United States.
Paul MakidonComparative Medicine, AbbVie, South San Francisco, CA, United States.
Lucas P J J NoldusNoldus Information Technology BV, Wageningen, Netherlands.
Yohann PotierTessera Therapeutics Inc., Cambridge, MA, United States.
Giorgio RosatiTecniplast S.p.A., Buguggiate, Italy.
Matt RuiterUnified Information Devices Inc., Lake Villa, IL, United States.
Laura SchaevitzRecursion Pharmaceuticals Inc., Salt Lake City, UT, United States.
Patrick SweeneyActual Analytics Ltd., Edinburgh, United Kingdom.
Megan R LaFolletteThe North American 3Rs Collaborative, Denver, CO, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In drug discovery and development, traditional assessment of human patients and preclinical subjects occurs at limited time points in potentially stressful surroundings (i.e., the clinic or a test arena), which can impact data quality and welfare. However, recent advances in remote digital monitoring technologies enable the assessment of human patients and preclinical subjects across multiple time points in familiar surroundings. The ability to monitor a patient throughout disease progression provides an opportunity for more relevant and efficient diagnosis as well as improved assessment of drug efficacy and safety. In preclinical

Indexed as

3Rs (reduce replace refine)digital biomarkersdrug discovery and developmenthome cagepreclinicalrodentstranslation

Identifiers

PMID35242017
PMCPMC8885444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.